Xatral® SR Tablet 5 mg 2x14
Xatral® LP 10mg Tablets
55 million men’s affected
Benign prostatic hyperplasia is the most frequent benign tumor affecting men.
It causes considerable discomfort because it is accompanied by an urgent and frequent need to urinate, particularly during the night. About one man in two is affected by these urinary symptoms after the age of 70, which represents a potential of more than 55 million men in 2004 and 59 million in 2009.
The disorder is under-diagnosed and under treated
A recent survey (MSAM-7) in seven countries (United States, France, Italy, United Kingdom, Spain, Germany and the Netherlands) involving 14,000 men over 50, revealed that only 19% of men with moderate symptoms were being treated and 43% of those with severe symptoms.
An increasing concern for quality of life should lead to a 50% increase in the number of patients being treated by the end of the decade. In addition, men over 50 suffering from benign prostatic hyperplasia are also four times more at risk of developing sexual dysfunction, an area in which there is growing demand for treatment.
If left untreated, benign prostatic hyperplasia may worsen and in the long term lead to acute urinary retention for which emergency surgery is frequently required.
Treatment of benign prostatic hyperplasia and of acute urinary retention
A unique position, the most dynamic drug in its category
- A uroselective alpha 1-blocker which does not affect sexual function. Xatral® is the first alpha 1-blocker on the market for the treatment of benign prostatic hyperplasia (BPH) symptoms with a selective effect on the urinary system. It is immediately active after administration of the first dose. Xatral® provides rapid and lasting relief of urinary symptoms, improves quality of life and is well tolerated, in particular as regards the impact on the cardiovascular system.
- The first alpha-blocker to obtain an indication as adjuvant treatment during episodes of acute urinary retention in addition to evaluation of symptomatic treatment of BPH, major clinical development work is proceeding on the main complication of the disorder, i.e. acute urinary retention (AUR), as regards both management of the acute phase and prevention.
Updated April 01, 2006